Medicilon appeared at the 25th SAPA-NE Annual Conference

On June 3, 2023, the 25th annual conference of SAPA-NE (Sino-American Pharmaceutical Professionals Association–New England/Boston) was successfully held in Boston, MA. Dr. Chunlin Chen, CEO of Medicilon, Dr. Zhenrong Guo, Executive Vice President of Pharmaceutical Research, and the Medicilon US team attended the annual conference and had pleasant and in-depth exchanges with many guests and experts during the conference. With professional quality, confident demeanor, and exhibitions as a platform, Medicilon fully demonstrates and delivers the values of "focus on innovation, win-win collaboration, client first, and loving and dedication". During the conference, the Medicilon team conducted in-depth exchanges with a lot of pharmaceutical colleagues, and discussed about the industry situation and market prospects.

From left to right Cindy Chen, Dr. Jun Li, Dr. Chunlin Chen, Dr. Zhenrong Guo, Dr. Yan Zhou.webp

From left to right: Cindy Chen, Dr. Jun Li, Dr. Chunlin Chen, Dr. Zhenrong Guo, Dr. Yan Zhou

Dr. Chunlin Chen of Medicilon was invited to give a wonderful speech on "Medicilon Strategy & 20 Years Experience for Dual Filing of IND to US FDA & China NMPA along with IPO at STAR Market". Since its establishment in 2004, Medicilon has provided drug R&D services to more than 2,000 clients around the world during the 20-year milestone. More than 330 new drug and generic drug projects that have participated in the research and development have obtained IND approval. In the past 20 years, Medicilon has grown together with the partners around the world.

Dr. Chen shared an in-depth analysis and case study.webp

Based on Medicilon's nearly 20 years of experience in IND filing, Dr. Chen shared an in-depth analysis and case study.

The 25th SAPA-NE Annual Conference attracted many professionals from the biotechnology and pharmaceutical industries to attend. Through intensive exchanges and discussion, the participants had in-depth discussion with industry organizations on how to meet the transformation in this challenging situation. Participants exchanged views on new trends in the industry in terms of new drug R&D, AI pharmaceuticals, technological innovation, pharmaceutical investment, and regulatory oversight.

The audience listened to Dr. Chen's speech.webp

The audience listened to Dr. Chen's speech.

As the Diamond Sponsor of the 25th SAPA-NE Annual Conference, the dinner event was exclusively sponsored by Medicilon. The well-arranged drinks and snacks allowed participants to enjoy the opportunity to communicate with different professionals after a busy meeting. The buffet dinner drew a perfect end to the busy day of business negotiation.

Medicilon, as a professional biopharmaceutical preclinical R&D service CRO, provides global pharmaceutical companies and research institutions with a full range of one-stop new drug R&D services that meet both China and US filing standards. Through this exhibition, the influence of the Medicilon has been further enhanced internationally. In order to realize the vision of "providing a full range of preclinical research services for global pharmaceutical companies, research institutions and all scientific researchers, and promoting the process of new drug research", Medicilon will continue to deepen the overseas high-end market, explore the European and American markets, and accelerate the pace of internationalization.

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客